Roche Holding AG engages in the diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases. The company provides diagnostic solutions, such as blood gas analysis; blood screening; cancer screening/monitoring; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring; coagulation routine and specialty testing; data management; diabetes monitoring; diabetes therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogeneous immuno assays; immunology; infectious diseases; intensive care testing; monitoring anti platelet therapy; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; physical fitness testing; platelet function testing; quality control service; real-time PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. Roche Holding AG has a strategic alliance with Wisconsin Diagnostic Laboratories; and collaboration agreements with Five Prime Therapeutics, Inc., Ionis Pharmaceuticals, Inc., and SQZ Biotechnologies Company. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RHHBY
Previous Symbol
CUSIPN/A
Phone41-61-688-1111
Debt
Debt-to-Equity Ratio0.53
Current Ratio1.28
Quick Ratio0.97
Price-To-Earnings
Trailing P/E Ratio15.85
Forward P/E Ratio13.67
P/E Growth1.89
Sales & Book Value
Annual Sales$54.15 billion
Price / Sales3.89
Cash Flow$2.5142 per share
Price / Cash12.29
Book Value$4.33 per share
Price / Book7.14
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees93,734
Outstanding Shares6,815,420,000
Market Cap$213.29 billion
OptionableNot Optionable
